Get the Stockscreener App
1.06
6.19%
-0.07
Propanc Biopharma Inc stock is traded at $1.06, with a volume of 551.58K.
It is down -6.19% in the last 24 hours and down -40.11% over the past month.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
See More
Previous Close:
$1.13
Open:
$1.15
24h Volume:
551.58K
Relative Volume:
0.31
Market Cap:
$13.37M
Revenue:
-
Net Income/Loss:
$-58.92M
P/E Ratio:
-0.0231
EPS:
-45.8429
Net Cash Flow:
$-401.10K
1W Performance:
-25.35%
1M Performance:
-40.11%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.04
$1.17
1-Week Range:
$1.04
$1.415
52-Week Range:
$1.04
$9.36
Propanc Biopharma Inc Stock (PPCB) Company Profile
Name
Propanc Biopharma Inc
Sector
Industry
Phone
61-03-9882-0780
Address
302/6 BUTLER STREET, CAMBERWELL, VICTORIA
Compare PPCB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PPCB
Propanc Biopharma Inc
|
2.87 | 244.39K | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
2.50 | 4.21B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.99 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.825 | 217.47M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2288 | 502.27M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.3695 | 0 | 0 | 0 | 0 | 0.00 |
Propanc Biopharma Inc Stock (PPCB) Latest News
$100 Million Deal Positions This Microcap at the Crossroads of Biotech and Digital Finance - The Globe and Mail
Propanc Biopharma announces initiative to pursue acquisition of DAT - TipRanks
Propanc Biopharma plans to acquire a digital asset financial company with a market value below its net asset value. - Bitget
Propanc Biopharma pursues strategic acquisition of DAT firms trading below market cap to net asset value - MarketScreener
Propanc Biopharma plans to acquire digital asset treasury companies By Investing.com - Investing.com UK
Propanc Biopharma, Inc. Announces Strategic Initiative to Acquire Undervalued Digital Asset Treasury Companies - Quiver Quantitative
Propanc Biopharma plans digital asset company acquisitions - Investing.com
Propanc Biopharma plans to acquire digital asset treasury companies - Investing.com
Propanc Biopharma (NASDAQ: PPCB) targets DAT firms below MNAV amid $17.6B ETH - Stock Titan
Propanc Biopharma, Inc. (PPCB) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital - The Manila Times
CORRECTION: Propanc Biopharma Announces Strategic Financing - GlobeNewswire
Up to $100M strategic financing — Propanc Biopharma issues $1M Series C convertible, warrants attached - Stock Titan
Propanc Biopharma announces up to $100M strategic financing from Hexstone Capital - MSN
Propanc Biopharma announces financing agreement up to $100M - TipRanks
Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital - The Manila Times
Propanc Biopharma announces strategic financing agreement of up to $100 million with Hexstone Capital - MarketScreener
Propanc Biopharma Announces Strategic Financing Agreement Of Up To $100 Million With Hexstone Capital - TradingView
Up to $100M strategic financing: Propanc Biopharma and Hexstone agree with $5.00 conversion price - Stock Titan
Ethereum treasury company Propanc Biopharma reaches up to $100 million strategic financing agreement with Hexstone Capital - Bitget
Propanc Biopharma Enters Securities Purchase Agreement - MSN
Propanc Biopharma enters agreement for Series C preferred stock private placement By Investing.com - Investing.com South Africa
Propanc Biopharma enters agreement for Series C preferred stock private placement - Investing.com UK
Propanc Biopharma receives certificate of grant from USPTO - MSN
Propanc Biopharma closes public offering, uplists to NASDAQ - MSN
Propanc Biopharma (OTCMKTS:PPCB) Stock Price Down 2.6% – Time to Sell? - Defense World
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development and $100M+ Digital Asset Treasury Strategy - MarketScreener
Propanc Biopharma reports major financial turnaround after Nasdaq uplisting By Investing.com - Investing.com Nigeria
Propanc Biopharma reports major financial transformation after Nasdaq listing - Investing.com
Propanc reports $100 million digital asset treasury plan, NASDAQ listing By Investing.com - Investing.com Nigeria
Propanc Biopharma plans $100M digital asset treasury strategy By Investing.com - Investing.com Australia
Propanc Biopharma reports total assets of $19.6M as of June 30 - TipRanks
Propanc Biopharma reports major financial turnaround after Nasdaq uplisting - Investing.com India
Propanc Biopharma reports major financial transformation after Nasdaq listing By Investing.com - Investing.com Australia
Propanc Biopharma Reports Fiscal Year-End Update and Strategic Developments Following Nasdaq Uplisting - Quiver Quantitative
Propanc reports $100 million digital asset treasury plan, NASDAQ listing - Investing.com India
Propanc Biopharma plans $100M digital asset treasury strategy - Investing.com
Propanc Reports End of Fiscal Year Highlights and Outlines - GlobeNewswire
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy - MarketScreener
$100M+ Digital Treasury Plan: Propanc Pursues Crypto Strategy After Nasdaq Uplisting and $19.6M Assets - Stock Titan
From Lab Bench to Blockchain: How Biotech is Reinventing Funding - The Globe and Mail
Propanc Biopharma, Inc. announced a financing transaction - MarketScreener
Does Propanc Biopharma (NASDAQ:PPCB) Have A Healthy Balance Sheet? - simplywall.st
Propanc Biopharma, Inc. SEC 10-K Report - TradingView
Propanc Biopharma prices $4M stock offering - MSN
Crypto and Cancer: How Biotech’s New Strategy Is Turning Heads - The Globe and Mail
Reviewing Immatics (NASDAQ:IMTX) & Propanc Biopharma (OTCMKTS:PPCB) - Defense World
Propanc receives US patent for proenzyme cancer treatment composition By Investing.com - Investing.com South Africa
Propanc receives US patent for proenzyme cancer treatment composition - Investing.com
Propanc Biopharma Receives Certificate of Grant for 'Proenzyme Composition” Patent from US Patent & Trademark Office - The Manila Times
Propanc Biopharma Receives Certificate of Grant for - GlobeNewswire
Propanc Biopharma Inc Stock (PPCB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):